Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

Healthy Volunteers Clinical Trial

Official title:

Phase 1 Randomized, Double-Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Repeat Administration (7 Days) of Ascending Oral Doses of Bendavia in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01786915
• Other study ID #: SPIO-102
• Status: Completed
• Phase: Phase 1
• First received: February 6, 2013
• Last updated: March 31, 2014
• Start date: February 2013
• Est. completion date: March 2013

Study information

• Verified date: March 2014
• Source: Stealth BioTherapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy adult males or females aged between 18 and 65 years of age with signed informed consent.

• Women who are not post-menopausal (without menstrual bleed for >24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study.

• Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or interuterine device (IUD) 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used.

Exclusion Criteria:

• Serum sodium level below the lower limit of the site's clinical laboratory normal range at the study qualification visit,

• Clinically significant laboratory abnormalities as determined by the Principal Investigator at laboratory screening

• Creatinine clearance calculated by the Cockcroft and Gault method calculated to be <90 mL/min for males and <80 mL/min for females

• Clinically significant abnormalities on physical examination,

• Body weight less than 60 kg or greater than 80 kg or a body mass index of less than 18 kg/m2 or greater than 32 kg/m2,

• Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems,

• History of seizures or history of epilepsy,

• History of serious (Principal Investigator judgment) mental illness,

• Participant in any research involving investigational product within 30 days before planned date of drug administration,

• Positive serology for HIV 1, HIV 2, HBsAg, or hepatitis C virus (HCV),

• Fever greater than 37.5°C at the time of planned dosing,

• Suspicion, or recent history, of alcohol or substance abuse,

• Donated blood or blood products within the past 30 days,

• Women who are pregnant or breastfeeding,

• Employee or family member of an employee of the investigational site,

• Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco product in the 30 days prior to screening,

• Subjects who are either unwilling to agree to refrain from use or found to be using:

• Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods

• Prescription medications from 14 days prior to and 7 days post treatment (excluding hormonal contraceptives)

• Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment

• Subjects having previous exposure to Bendavia

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Bendavia 10mg

• Bendavia 50mg

• Placebo

Locations

Country	Name	City	State
United States	Clinical Pharmacology of Miami Inc	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Stealth BioTherapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 1 in each cohort.	Blood drawn at pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose	No
Primary	Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 7 in each cohort.	Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.	Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose	No
Primary	Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 1 in each cohort.	Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose	No
Primary	Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 7 in each cohort.	Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.	Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose	No
Primary	Mean Area Under the Curve (AUC) from 0-24 hours on Day 1 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.	Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12 and +18 hours and pre-D2-dose (approximately 24 hours post-D1-dose) will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose	No
Primary	Mean Area Under the Curve (AUC) from 0-24 hours on Day 7 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.	Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours post-D7-dose will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose	No
Primary	Ratio of AUC0-24h calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].	Mean AUC (0-24hr) calculated at Day 7 as the ratio of Mean AUC (0-24hr) calculated at Day 1 will be calculated for each Bendavia-treated cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose	No
Primary	Number of adverse events observed with and without Bendavia	Adverse events will be tabulated by treatment group. No statistical analysis will be performed.	From time of study drug administration to End of Study (Day 10)	Yes
Secondary	Mean change in concentration of urinary 8-isoprostane (pg/mg creatinine) from pre-dose through to study Day 10 for each cohort.	Spot urine samples will be collected at pre-dose on each day of dosing (Days 1-7) and at 24, 48 and 72 hours post-Day7-dose for assay of 8-isoprostane (8-EPIPGF2a) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-EPIPGF2a/creatinine for each subject by cohort.	Prior to dosing (Day 1, 0hr) to Study Day 10	No
Secondary	Mean change in concentration of urinary 8-hydroxy-2-deoxyguanosine (ng/mg creatinine) from pre-dose through to study Day 10 for each cohort.	Spot urine samples will be collected at pre-dose on each dosing day (Days 1-7) and at 24, 48 and 72 hours post-D7-dose for assay of 8- hydroxy-2-deoxyguanosine (8-OHDG) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-OHDG/creatinine for each subject by cohort.	Prior to dosing (Day 1, 0hr) to Study Day 10	No
Secondary	Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.	Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for M1 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M1 is defined as the mean of AUC (0-24) reported for each subject by cohort.	Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose	No
Secondary	Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.	Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for M2 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M2 is defined as the mean of AUC (0-24) reported for each subject by cohort.	Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose	No
Secondary	Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.	Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for M1 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M1 is defined as the mean of AUC (0-24) reported for each subject by cohort.	Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose	No
Secondary	Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.	Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for M2 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M2 is defined as the mean of AUC (0-24) reported for each subject by cohort.	Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose	No
Secondary	Ratio of AUC0-24h for M1 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].	Mean AUC (0-24hr) for M1 calculated at Day 7 as the ratio of Mean AUC (0-24hr) for M1 calculated at Day 1 will be calculated for each Bendavia-treated cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose	No
Secondary	Ratio of AUC0-24h for M2 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].	Mean AUC (0-24hr) for M2 calculated at Day 7 as the ratio of Mean AUC (0-24hr) for M2 calculated at Day 1 will be calculated for each Bendavia-treated cohort.	Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose	No